-
Traffic stop: Warsaw's celebrity birds on perilous urban quest
-
Drivers help study road-trip mystery: what became of bug splats?
-
In Mauritania, Mali refugees hope Russia will depart their homeland
-
Oil strikes 4-year peak, stocks rise
-
Under-fire UK PM heckled after Jewish-targeted stabbings
-
King Charles to honor US troops on final day of visit
-
US first-quarter growth rebounds less than expected as inflation surges
-
Ruud's Madrid title defence ended by Belgian Blockx
-
Manila landfill fire leaves locals gasping
-
Statue pops up on London plinth bearing Banksy's name
-
Iran's supreme leader defies US blockade as oil prices soar
-
Ukraine wants details of Russia's army parade truce offer
-
LIV Golf looking for new partners amid Saudi pullout reports
-
Cambodia deports more than 600 Thais linked to cyberscams: minister
-
Mainoo signs new five-year Man Utd contract
-
Mainoo signs new Man Utd contract
-
White House against Anthropic expanding Mythos model access: report
-
Oil strikes 4-year peak, stocks diverge as central banks in focus
-
Gaza flotilla organisers say 211 activists 'kidnapped' by Israel
-
Oil crisis fuels calls to speed up clean energy transition
-
European rocket blasts off with Amazon internet satellites
-
Nigerian airlines avert shutdown as Mideast war hikes fuel prices
-
Eurozone economy barely grows in first months of 2026
-
Press freedom at lowest level in 25 years: RSF
-
ArcelorMittal boosts sales but profits squeezed
-
Burnley boss Parker leaves club after relegation
-
Nigerian airlines avert shutdown as Iran war hikes fuel prices
-
IPL fines Rajasthan's Parag for vaping in dressing room
-
German growth beats forecast but energy shock looms
-
Under-fire UK boosts security for Jews after latest attack
-
Afghan women footballers celebrate 'historical moment'
-
Iran defies Trump's blockade as oil prices soar
-
Air France-KLM trims 2026 outlook over Middle East war impact
-
Oil surges to four-year high on Trump blockade warning
-
Teen with 30 tortoises under clothes nabbed at Thai airport
-
Hero's welcome in Kenya for marathon record-breaker Sawe
-
Oil surges 7% to top $126 on Trump blockade warning
-
Volkswagen warns of more cost cuts as profits plunge
-
Rolls-Royce confident on profits despite Mideast war disruption
-
French economy records zero growth in first quarter
-
Carmaker Stellantis swings back into profit as sales climb
-
Trump warns Iran blockade could last months, sending oil prices soaring
-
Pistons stay alive, Lakers can't stop Rockets
-
No 'meaningful' shift from social media sites after Australia teen ban: govt report
-
Denmark's Soren Torpegaard Lund to 'stay true' at Eurovision
-
Marathon brothers run Ireland in race to find dementia cure
-
Inoue wary of 'clever' Nakatani in sold-out Tokyo superfight
-
Australian Jewish group warned of 'attack' before Bondi mass shooting: inquiry
-
Mamdani calls on King Charles to return Koh-i-Noor diamond
-
New Zealand mosque killer loses bid to overturn convictions
Relief Therapeutics Advances Publication of 2025 Half-Year Report
GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has advanced the publication date of its 2025 half-year report. Originally scheduled for release on August 27, 2025, the report will now be published on August 14, 2025, ahead of market opening.

The change in publication date is due to the Company's anticipated early completion of the report. The half-year report, which will include a shareholder update and interim financial statements, will be available on Relief's website at the time of publication.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.
CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
[email protected]
SOURCE: Relief Therapeutics Holding SA
View the original press release on ACCESS Newswire
H.Gonzales--AT